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Abstract
Background: Parkinson’s disease (PD) is characterized by progressive loss of midbrain dopaminergic neurons,
resulting in motor dysfunctions. While most PD is sporadic in nature, a significant subset can be linked to either
autosomal dominant or recessive mutations. PARK2, encoding the E3 ubiquitin ligase, parkin, is the most frequently
mutated gene in autosomal recessive early onset PD. It has recently been reported that PD-associated gene
products such as PINK1, α-synuclein, LRRK2, and DJ-1, as well as parkin associate with lipid rafts, suggesting that the
dysfunction of these proteins in lipid rafts may be a causal factor of PD. Therefore here, we examined the
relationship between lipid rafts-related proteins and parkin.
Results: We identified caveolin-1 (cav-1), which is one of the major constituents of lipid rafts at the plasma
membrane, as a substrate of parkin. Loss of parkin function was found to disrupt the ubiquitination and
degradation of cav-1, resulting in elevated cav-1 protein level in cells. Moreover, the total cholesterol level and
membrane fluidity was altered by parkin deficiency, causing dysregulation of lipid rafts-dependent endocytosis.
Further, cell-to-cell transmission of α-synuclein was facilitated by parkin deficiency.
Conclusions: Our results demonstrate that alterations in lipid rafts by the loss of parkin via cav-1 may be a causal
factor of PD, and cav-1 may be a novel therapeutic target for PD.
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Background
Parkinson’s disease (PD) is a common neurodegenera-
tive disease characterized by progressive degeneration
of midbrain dopaminergic neurons, resulting in motor
dysfunction [1]. Although the majority of PD occurs spor-
adically, mutations in several genes including SNCA,
LRRK2, parkin, PINK1, and DJ-1 have been identified in
patients with familial PD, providing enormous insight into
the molecular pathways underlying the neurodegeneration
shown in PD [2]. Despite the fact that it has not yet been
fully unveiled, oxidative stress, mitochondrial damage and
defects of protein quality control system are known to
play a critical role in the pathogenesis of PD [1]. Recently,
prion-like propagation of α-synuclein, encoded by SNCA,
a PD-associated gene, has also been proposed to play a
role in the progression of PD [3–5].
Parkin is a 465 amino acid protein that possesses E3
ubiquitin ligase activity, and familial type mutations in
parkin are predicted to be loss of function [6], suggest-
ing that loss of parkin activity results in the gradual
and abnormal accumulation of parkin substrates,
which may cause familial PD. Mutations in the parkin
gene have been revealed to be the most common cause
of autosomal recessive early onset PD, which causes
50 % of autosomal recessive early onset PD [7]. In
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addition, increasing evidence indicates that parkin is
also inactivated in patients with sporadic PD by s-
nitrosylation, tyrosine phosphorylation, and oxidation
[8], suggesting that parkin also plays a critical role in
the pathogenesis of sporadic PD. Accordingly, the iden-
tification of parkin substrates is important to elucidate the
exact roles of parkin in the pathogenesis of PD. To date,
several substrates including CDCrel-1 [9], Pael-R [10],
synphilin-1 [11], and PARIS [12] have been identified and
great efforts is continuously being made in the identifica-
tion of novel substrates to elucidate the pathogenesis of
PD.
Parkin is localized mainly in the cytosol, however, a
small proportion has been shown to be localized in
membranes including in lipid rafts [13–15]. Lipid rafts
are specialized membrane microdomains that are enriched
in cholesterol, glycosphingolipids, and glycosylphosphati-
dylinositol (GPI)-anchored proteins, which serve as
organization centers for the assembly of signaling mole-
cules, and influence membrane fluidity and trafficking of
membrane proteins, and regulate receptor-mediated signal
transduction and exo/endocytosis [16, 17]. Caveolins and
flotillins have been shown to be integral components of
lipid rafts [18]. Recently, increasing evidence has indicated
that lipid rafts may play an important role in neurodegen-
eration [19, 20]. In particular, many PD-associated gene
products such as α-synuclein [21], PINK1 [22], LRRK2
[23], and DJ-1 [24], as well as parkin [13], have also been
reported to associate with lipid rafts, implying that func-
tional alteration of lipid rafts by these proteins may be one
of the common pathological mechanisms of PD. We
recently reported that DJ-1 regulates lipid rafts-dependent
endocytosis [24], however, the roles of other proteins in
lipid rafts have yet to be explored.
In the present study, we explore whether parkin
regulates the components of lipid rafts and whether
loss of parkin induces functional alterations in lipid
rafts. In addition, we explore the association between
the functional alterations in lipid rafts induced by loss
of parkin and the propagation of α-synuclein, which
has been recently proposed to be a causal factor of
the progression of PD.
Results
Loss of parkin leads to an increase in caveolin-1 (cav-1)
To explore whether loss of parkin induces functional
alterations in lipid rafts, we first compared the expression
level of the well-known lipid rafts marker proteins,
caveolin-1 (cav-1), cav-2, flotillin-1 (flot-1), and flot-2
using WT and parkin KO MEF cells. Interestingly, we ob-
served that the level of cav-1 was increased in parkin KO
MEF cells specifically, while the levels of other proteins
were not changed (Fig. 1a). Confocal microscopic analysis
also shows an increase of cav-1 protein in parkin KO MEF
cells compared with WT MEF cells (Fig. 1b). To investi-
gate the distribution of increased cav-1 in parkin KO MEF
cells, lipid rafts were isolated based on their solubility in
1 % Triton X-100 on ice [24, 25]. As shown in Fig. 1c, the
increase in cav-1 protein in parkin KO MEF cells was ob-
served only in the cold Triton X-100 insoluble fraction.
Moreover, the distribution of the other proteins was not
changed. The expression of parkin was relatively lower
in MEF cells than that in neurons. Therefore, we loaded
a 4-fold higher amount of protein for Western blotting
of parkin and a small proportion of parkin was detected
in the cold Triton X-100 insoluble fraction. This is also
in agreement with a previous study [13]. To test
whether parkin regulates cav-1 expression specifically,
we overexpressed flag-parkin in parkin KO MEF cells.
The overexpression of parkin in parkin KO MEF cells
rescued cav-1 level without any change in the levels of
other proteins (Fig. 1d), suggesting that parkin regulates
cav-1 specifically.
Parkin induces the degradation of cav-1 through the
proteasome-dependent pathway
To investigate in more detail the manner in which the
loss of parkin leads to an increase in cav-1, we tested the
mRNA level of cav-1 in both WT and parkin KO MEF
cells. Quantitative RT-PCR shows that the mRNA level of
cav-1, as well as that of cav-2, flot-1, and flot-2 were not
different between the two cell lines (Fig. 2a), suggesting
that parkin does not regulate cav-1 at the transcriptional
level. Parkin regulates protein degradation as an E3
ubiquitin ligase [6]. In addition, cav-1 has been reported
to be partially degraded by the ubiquitin proteasome
system (UPS) [26, 27], speculating that parkin may regu-
late cav-1 degradation via the UPS. To confirm this
hypothesis, WT and parkin KO MEF cells were treated
with cycloheximide (CHX), an inhibitor of protein
synthesis, and the expression of cav-1 was assessed
using Western blotting. As shown in Fig. 2b, the degrad-
ation of cav-1 in WT MEF cells was significantly faster
than in parkin KO MEF cells. In addition, while treat-
ment with the proteasomal inhibitors, MG-132 and
lactacystin, led to an accumulation of cav-1 in WT MEF
cells, it did not further enhance the steady state levels of
cav-1 in parkin KO MEF cells. (Fig. 2c and d). Confocal
microscopic analysis confirmed this observation (Fig. 2e),
suggesting that parkin regulates cav-1 degradation via the
UPS. These results also prompted speculation that cav-1
may be a substrate of parkin, thus, we tested the inter-
action between the two proteins. As shown in Fig. 3a, both
flag-parkin and cav-1-EGFP were overexpressed in parkin
KO MEF cells, and immunoprecipitation shows their
interaction. Antibody staining of endogenous parkin
and cav-1 in MEF cells shows the colocalization of
both proteins (Fig. 3b), which was also confirmed using
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an in situ proximity ligation assay (PLA) (Fig. 3c), sug-
gesting that parkin interacts with cav-1. Next, in order
to investigate whether parkin ubiquitinates cav-1, we
transfected parkin KO MEF cells with flag-parkin,
His-ubiquitin, and cav-1-EGFP, which resulted in an
increase in the ubiquitination of cav-1-EGFP by flag-
parkin (Fig. 3d). Furthermore, mutants of parkin that
have been identified in patients with familial PD did not
rescue the increase in cav-1 by loss of parkin (Fig. 3e), sug-
gesting that parkin mediates the ubiquitination of cav-1,
thereby targeting cav-1 to the proteasome for degradation.
Cholesterol level, membrane fluidity, and lipid
rafts-dependent endocytosis were altered in parkin KO
MEF cells
Cav-1 is known to regulate cholesterol transport [28, 29].
Accordingly, we measured the total cellular cholesterol
level. As shown in Fig. 4a, the total cholesterol level in
parkin KO MEF cells was slightly increased compared
with that in WT MEF cells. Upon measurement of mem-
brane fluidity using C-laurdan [30], the calculated GP
value in parkin KO MEF cells was higher than that in WT
MEF cells, suggesting that the membrane fluidity was de-
creased (Fig. 4b). This indicates that loss of parkin leads
to an alteration in the total cholesterol level and mem-
brane fluidity. Cav-1 has also been shown to regulate
lipid rafts-dependent endocytosis [31]. In addition, the
cholesterol level influences membrane fluidity, which
can affect endocytosis [32]. Accordingly, in order to in-
vestigate whether parkin regulates lipid rafts-
dependent endocytosis via cav-1, we performed an in
vitro endocytosis assay using LacCer as a marker of
lipid rafts-dependent endocytosis [31, 33] and transferrin
as a marker of clathrin-dependent endocytosis [34, 35]. As
shown in Fig. 4c, the level of endocytosis of LacCer was
higher in parkin KO MEF cells than in WT MEF cells,
however, endocytosis of transferrin was not different be-
tween the two cell lines. Furthermore, to confirm that the
increased level of endocytosis of LacCer in parkin KO
MEF cells was due to the accumulation of cav-1, we
downregulated cav-1 using siRNA. Transfection of cav-1




























































































































   
   
   
   






Fig. 1 Loss of parkin leads to an increase in cav-1. a Lysates prepared from WT and parkin KO MEF cells were analyzed by SDS-PAGE and Western
blotting, and the band intensity of three independent experiments was quantified. b WT and parkin KO MEF cells were stained with anti-caveolin-1
(red) and observed by confocal microscopy. The intensity of three independent experiments was quantified. The mean intensity value of each
experiment was acquired by measuring the intensity of at least 100 cells. Scale bar indicates 10 μm. c WT and parkin KO MEF cells were lysed
in ice-cold 1 % Triton X-100 buffer and fractionated as described in ‘Methods’. The soluble and insoluble fractions were then analyzed using
Western blotting. The transferrin receptor (TfR) was used as a marker for the non-lipid raft fractions. Band intensity of three independent experiments
was quantified. d Parkin KO MEF cells were transfected with a plasmid for flag-parkin, and after 48 h, lysates were analyzed by SDS-PAGE and Western
blotting, and the band intensity of three independent experiments was quantified. P values were determined using a Student’s t test. ** p < 0.01
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and endocytosis of LacCer in parkin KO MEF cells was
rescued by the downregulation of cav-1 expression
(Fig. 4c), suggesting that parkin regulates lipid rafts-
dependent endocytosis via cav-1.
Parkin regulates lipid rafts-dependent endocytosis via
cav-1 in neurons
We performed all the experiments in MEF cells, thus, in
order to confirm whether parkin regulates cav-1 in
neurons, we suppressed parkin expression in primary
cortical neurons using an shRNA lentiviral system. As
shown in Fig. 5a, parkin level was efficiently suppressed in
neuron by the shParkin lentivirus, and as a result, cav-1
expression was increased, suggesting that parkin regulates
cav-1 in neurons. In addition, an in situ PLA was per-
formed in primary cortical neurons, and the interaction of
parkin with cav-1 was observed (Fig. 5b). The total choles-
terol level was increased (Fig. 5c), and the membrane flu-
idity of parkin KD neurons was decreased compared with
that of WT neurons (Fig. 5d). Moreover, the endocytosis
of LacCer was enhanced by parkin knockdown (Fig. 5e),
which is in agreement with our data in MEF cells (Fig. 4),
suggesting that parkin regulates lipid rafts-dependent
endocytosis via cav-1 in neurons.
Loss of parkin facilitates the transmission of α-synuclein
Previously, we have demonstrated that α-synuclein is
internalized by lipid rafts-dependent endocytosis in
BV-2 cells, a murine microglial cell line [36]. To inves-
tigate whether parkin regulates the internalization of
α-synuclein into neurons, we used the two chamber
culture system using human α-synuclein overexpressing
SH-SY5Y cells, which showed the efficient internalization
of cell-released α-synuclein into neighboring cells [36, 37].
Following staining with α-synuclein using a human α-
synuclein-specific antibody in a co-culture of α-synuclein
overexpressing SH-SY5Y cells and rat primary cortical
neurons, cell-derived α-synuclein was observed to be
internalized in much higher amounts into rat primary cor-
tical neurons suppressing parkin expression than into con-
trol neurons (Fig. 6a), suggesting that loss of parkin could
regulate the propagation of α-synuclein. To rule out the
possibility that the higher α-synuclein intensity in rat pri-
mary cortical neurons suppressing parkin expression was
due to abnormal degradation of α-synuclein by dysfunc-
tion of parkin, we determined the endogenous α-synuclein
level following suppression of parkin expression in pri-
mary neurons. The level of endogenous α-synuclein was
not different between the primary cortical neurons infected
with parkin (shParkin) and with non-targeting shRNA
lentivirus (shNT) (Fig. 6b), suggesting that parkin regulates
α-synuclein transmission rather than degradation.
Discussion
Increasing evidence indicates that alteration in lipid rafts





































































Fig. 2 Parkin induces the degradation of cav-1 through the proteasome-dependent pathway. a Real-time RT-PCR was performed as described in
‘Methods’. WT and parkin KO MEF cells were incubated with with 10 μg/ml cyclohexamide (CHX) for the indicated times b 10 μM MG132 for
3.5 h c and 10 μM lactacystin for 3.5 h d Lysates were analyzed by SDS-PAGE and Western blotting. P values were determined using a two way
ANOVA, **p < 0.01. e WT and parkin KO MEF cells cultured on poly-D-lysine coated glass were incubated with 10 μM MG132 for 3.5 h, stained
with anti-cav-1 (red), and then observed by confocal microscopy. Blue indicates DAPI staining. Scale bar indicates 10 μm
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Alterations in lipid composition have been reported in
lipid rafts from AD and PD human brain cortex [38, 39].
Alterations in lipid rafts proteins have also been observed
in AD and amyotrophic lateral sclerosis mouse models
[40, 41]. Based on these observations and data from sev-
eral studies, altered lipid rafts organization has also
been proposed to be a common causative factor of many
neurodegenerative diseases [19, 20].
In the present study, we identified cav-1 as a novel
substrate of parkin. Cav-1 is a main structural protein
component of caveolae, a subset of lipid rafts [42]. We
observed that among the main structural protein com-
ponents of lipid rafts, cav-1 is specifically accumulated
in parkin KO MEF cells and primary neurons suppress-
ing parkin expression. We also demonstrated that WT
parkin ubiquitinates cav-1 for degradation. The N-
terminal region of cav-1 has been reported to be exclu-
sively ubiquitinated [27], suggesting that parkin can
ubiquitinate any of the N-terminal lysine residues of
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Fig. 3 Parkin interacts with and ubiquitinates cav-1. a Parkin KO MEF cells were transfected with plasmids for flag-parkin and cav-1-EGFP for 48 h,
and then the lysates were immunoprecipitated with anti-flag and anti-EGFP antibodies, respectively, followed by Western blotting. b WT MEF cells
cultured on poly-D-lysine-coated glass were co-stained with anti-cav-1 (red) and anti-parkin (green), and observed by confocal microscopy. Blue
indicates DAPI staining. Scale bar indicates 10 μm. c An in situ PLA assay was performed in WT MEF cells, as described in ‘Methods’. Red PLA spots
represent interactions between parkin and cav-1. Blue indicates DAPI staining. Scale bar indicates 10 μm. d Parkin KO MEF cells were transfected
with the indicated combinations of plasmids for flag-parkin, His-ubiquitin (His-Ub), and cav-1-EGFP for 48 h, and were then incubated with 10 μM
MG132 for 3.5 h. The lysates were immunoprecipitated with an anti-EGFP antibody, followed by Western blotting. e Parkin KO MEF cells were transfected
with plasmids for flag-tagged WT parkin and mutants (T240R and T415N) for 48 h, and the lysates were then analyzed by SDS-PAGE and Western blotting.
The band intensity of three independent experiments was quantified. P values were determined using one way ANOVA. ** p< 0.01
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associated with familial PD, failed to regulate cav-1
expression, suggesting that accumulation of cav-1 may be
involved in the pathogenesis of PD. Cav-1 is a 21-24 kDa
membrane protein, which is a member of the caveolin
family consisting of cav-1, 2, and 3. Caveolins have diverse
functions including membrane-initiated intracellular sig-
naling via the clustering of proteins, the segregation of
proteins, and the trafficking of proteins to and from the
membrane and lipid transport [43, 44]. They are also
known to be involved in diverse pathologies including
carcinogenesis, insulin resistance, and aging [45]. Although
the roles of cav-1 in the CNS have been relatively less stud-
ied, an association between cav-1 and neurodegeneration
and aging has been reported. Cav-1 expression levels in the
hippocampus are upregulated in AD compared with con-
trol brains [46]. An age-related increase in cav-1 has also
been reported [47–49]. On the contrary, loss of cav-1 in
young mice has been reported to accelerate neurode-
generation and aging [50, 51]. Although the relation-





































































































Fig. 4 Cholesterol level, membrane fluidity, and lipid rafts-dependent endocytosis are altered in parkin KO MEF cells. a The total cholesterol level
was measured in WT and parkin KO MEF cells, as described in ‘Methods’. P values were determined using a Student’s t-test. *p < 0.05. b WT and
parkin KO MEF cells were stained with 0.5 μM C-laurdan, and then observed by two-photon microscopy. Images were processed to obtain GP
values as described in ‘Methods’. Scale bar indicates 10 μm. c WT and KO MEF cells transfected with siRNA for non-targeting (siCon) and cav-1
(siCav-1) for 48 h, were incubated with 50 nM BOIPY® FL C5-Lactosylceramide and 2.5 μg/ml rhodamine-conjugated transferrin for the indicated
times. The cells were then fixed and observed by confocal microscopy. Scale bar indicates 20 μm. The intensity of three independent experiments
was quantified. The mean value of intensity of each experiment was acquired by measuring the intensity of at least five random fields. P values
were determined using a Two way ANOVA. **p < 0.01. d Parkin KO MEF cells were transfected with siRNA for non-targeting (SiCon) and cav-1
(SiCav-1) for 48 h, and then the lysates were analyzed by SDS-PAGE and Western blotting
Cha et al. Molecular Neurodegeneration  (2015) 10:63 Page 6 of 13
is controversial, cav-1 may be a critical control point
for cellular aging [52]. Given that aging is the greatest
risk factor for the development of PD [53, 54], dysregu-
lation of cav-1 by parkin inactivation may accelerate
senescence, causing neurodegeneration. Interestingly,
overexpression of α-synuclein, a PD-associated gene
product, also upregulates cav-1 expression, which me-
diates α-synuclein neurotoxicity [55, 56], supporting





















































































































Fig. 5 Parkin regulates lipid rafts-dependent endocytosis via cav-1 in neurons. a Rat primary cortical neurons were infected with shRNA lentivirus
for non-targeting (Sh-NT) and parkin (Sh-Parkin) 11 days after plating, and cultured for a further 3 days. The lysates were analyzed by SDS-PAGE and
Western blotting. b An in situ PLA assay was performed in rat primary cortical neurons, as described in ‘Methods’. Red PLA spots represent interactions
between parkin and cav-1. Blue indicates DAPI staining. Scale bar indicates 20 μm. c The total cholesterol level was measured, as described in ‘Methods’.
P values were determined using One way ANOVA. *p< 0.05. d Rat primary cortical neurons were infected with shRNA lentivirus for non-targeting (Sh-NT)
and parkin (Sh-Parkin), stained with 0.5 μM C-laurdan, and then observed by two-photon microscopy. Images were processed for obtaining GP values as
described in ‘Methods’. Scale bar indicates 20 μm. e Rat primary cortical neurons were infected with shRNA lentivirus for non-targeting (Sh-NT) and parkin
(Sh-Parkin) and incubated with 50 nM BOIPY® FL C5-Lactosylceramide The cells were then fixed and observed by confocal microscopy. Scale bar indicates
20 μm. The intensity of three independent experiments was quantified. The mean value of intensity of each experiment was acquired by measuring the
intensity of at least five random fields. P values were determined using a Two way ANOVA. **p< 0.01
Cha et al. Molecular Neurodegeneration  (2015) 10:63 Page 7 of 13
Cav-1 is well-known to play a role in the transport of
cholesterol from the ER to the plasma membrane caveolae
[28]. We demonstrated that accumulation of cav-1 by the
loss of parkin increased the total cellular cholesterol level
and decreased membrane fluidity. Upon cav-1 overexpres-
sion, total lipid cholesterol has been reported to be in-
creased [57], which is in agreement with our study.
Dysregulation of cholesterol metabolism has been largely
reported to be associated with many neurodegenerative
diseases including AD, PD and Huntington’s disease (HD)
[58]. In a model of HD, mutant htt-expressing neurons ex-
hibited cholesterol accumulation [59] and increased cav-1
expression. Loss or reduction of cav-1 expression in a
mouse model of HD suppresses the motor phenotype
[60], suggesting that cav-1 is a critical factor for neurode-
generation and could be a novel therapeutic target for
many neurodegenerative diseases including PD. Changes
in membrane fluidity by a variety of factors, as well as the
alteration of cholesterol content, may affect membrane
signaling properties. It has been reported that lipid
changes in AD lipid rafts increase membrane order
and viscosity in these domains [61]. APP/PS1 double
transgenic mice exhibit age-dependent lipid rafts
changes towards higher viscosity [62]. In addition, lipid
rafts in patients with PD are notably more viscous and
liquid-ordered than age-matched controls, which may ul-
timately contribute to progressive neuronal dysfunction
[39], suggesting that subtle changes in membrane fluidity
as a result of parkin dysfunction may affect a variety of
membrane signaling, accelerating neurodegeneration.
We also demonstrated that accumulation of cav-1 by
loss of parkin increased lipid rafts-dependent endocytosis.
Fallon et al. [13] reported that EGFR endocytosis is accel-
erated in parkin-deficient cells, however, there is no differ-
ence in transferrin endocytosis. In addition, EGFR
signaling is reduced in parkin KO mouse brain, proposing
that the interaction between parkin and Eps15 plays a role
in EGFR trafficking and signaling [63]. Based on previous
reports that EGFR endocytosis is lipid rafts-dependent
[64], it is in agreement with our findings that parkin regu-
lates lipid raft-dependent endocytosis. Moreover, consider-
ing previous reports that EGFR signaling is attenuated by
cav-1 overexpression in senescent cells [47] and breast
cancer [65], attenuated EGFR signaling shown in parkin
KO mouse brain is speculated to be partially mediated by
the accumulation of cav-1.
Recent studies have highlighted prion-like mecha-
nisms of propagation of aggregation prone proteins in-
cluding α-synuclein, tau, and polyglutamine protein,
which are associated with many neurodegenerative dis-
eases and are anticipated to provide great insight into
the pathogenesis of neurodegenerative diseases [66, 67].
In addition, numerous studies indicate functional in-
















































Fig. 6 Loss of parkin facilitates the transmission of α-synuclein. a Rat primary cortical neurons were infected with shRNA lentivirus for non-targeting
(Sh-NT) and parkin (Sh-Parkin) 11 days after plating, cultured for a further 2 days, and then co-cultured with α-synuclein overexpressing SH-SY5Y cells
for 24 h. The cells were stained with an anti-human α-synuclein (red) antibody and observed using confocal microscopy. Blue indicates DAPI staining.
Scale bar indicates 20 μm. b Rat primary cortical neurons were infected with shRNA lentivirus for non-targeting (Sh-NT) and parkin (Sh-Parkin) 11 days
after plating and cultured for a further 3 days. The lysates were analyzed by SDS-PAGE and Western blotting
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involvement in common pathogenic mechanisms caus-
ing PD. Parkin protects against the toxicity associated
with α-synuclein [68–70]. Transgenic mice expressing
a mutant parkin exhibit accumulation of proteinase K-
resistant α-synuclein [71]. GBA1 gene depletion, a
strong genetic risk factor for PD, has recently been reported
to enhance cell-to-cell transmission of α-synuclein [72]. In
the present study, we observed that loss or reduction of
parkin facilitated cell-to-cell transmission of α-synuclein,
speculating that dysfunction of parkin may be involved in
prion-like propagation of α-synuclein. Interestingly, com-
pared with enhancement of lipid rafts-dependent endocyto-
sis assessed by LacCer in parkin KD neurons, enhancement
of α-synuclein uptake was much higher in parkin KD
neurons, indicating that other endocytic pathways may be
involved in α-synuclein uptake into neurons, and that par-
kin may also regulate these pathways. Parkin expression is
known to be necessary for Lewy body formation [11] and
parkin-mediated inclusion body formation is viewed as part
of the cellular defense mechanism rather than a detrimental
event [73, 74]. Accordingly, increased α-synuclein up-
take without inclusion body formation in neurons
with parkin depletion may be more detrimental. How-
ever, it has also been reported that the absence of
parkin has no impact on the onset or progression of
the phenotype induced by overexpression of human
A53T α-synuclein [75]. Currently, it has not been
fully unveiled as to what extent prion-like propagation
of α-synuclein contributes to the pathogenesis of PD.
Nevertheless, the association between the dysfunction
of parkin and prion-like propagation of α-synuclein
needs to be re-evaluated.
In addition to involvement in the pathogenesis of
PD, parkin has been reported to function in metabol-
ism [76, 77] and cancer [78] through the regulation
of a variety of processes including receptor trafficking
and mitochondrial quality control. Cav-1 has been
well-reported to be associated with cancer and metab-
olism [79]. Accordingly, the involvement of parkin in
many physiological and pathological conditions such
as metabolism and cancer may be mediated by cav-1
expression.
Conclusions
We observed the accumulation of cav-1 in parkin KO
MEF cells and parkin KD neurons and identified cav-1
as a novel substrate of parkin. Accumulation of cav-1 by
parkin dysfunction altered the total cholesterol levels
and membrane fluidity, causing alterations in lipid rafts-
dependent endocytosis. In addition, parkin dysfunction
accelerated propagation of α-synuclein into neighboring
cells, which may contribute to the progression of PD.
Accordingly, regulation of cav-1 may be a novel target to
elucidate the pathogenesis of PD.
Methods
Antibodies and reagents
The following primary antibodies (Abs) were used:
anti-caveoin-1 (BD bioscience, Franklin Lakes, NJ; Abcam,
Cambridge, MA), anti-caveolin-2 (BD bioscience), anti-
flotillin-1 (BD bioscience, Franklin Lakes), anti-flotillin-2
(BD bioscience, Franklin Lakes), anti-CD71 (transferrin
receptor, Santa Cruz Biotechnology, Santa Cruz, CA),
anti-parkin (Santa Cruz Biotechnology, Santa Cruz, CA),
anti-flag (Sigma-Aldrich, St. Louis, MO) and biotin conju-
gated anti-CTxB (Sigma-Aldrich, St. Louis, MO), anti-myc
(Sigma-Aldrich, St. Louis, MO) and anti-actin (Santa Cruz
Biotechnology, Santa Cruz, CA). MG-132 and lactacystin
were purchased from Sigma-Aldrich (St. Louis, MO).
Cycloheximide was purchased from Calbiochem (Denvers,
MA). Rhodamine-conjugated transferrin and BOIPY® FL
C5-Lactosylceramide were purchased from Invitrogen/
Molecular Probes (San Dieogo, CA).
Cell culture and transfection
WT and parkin KO mouse embryonic fibroblast (MEF)
cells, kindly provided by Dr. Youle RJ (National Institutes
of Health, Bethesda), and human α-synuclein overexpress-
ing SH-SY5Y cells [36, 37] were grown in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
10 % fetal bovine serum (FBS). Cells were transfected
using lipofectamine 2000 or lipofectamine RNAiMax
(Invitrogen, Carlsbad, CA) according to the manufac-
turer’s instruction. After 48 or 72 h of transfection, cells
were used for Western blotting or imaging analysis.
Primary cortical neurons were cultured from Sprague-
Dawley rat embryos at embryonic day 18, and maintained
in Neurobasal medium (Invitrogen, Carlsbad, CA) with L-
glutamine and B-27 supplement (Invitrogen, Carlsbad, CA).
All animal procedures used in the present study were con-
ducted according to the guidelines established by the Ajou
University School of Medicine Ethics Review Committee
for Animal Experiments.
Constructs
The plasmid for flag-WT parkin was kindly provided by
Dr. Chung KC (Yonsei University, Seoul), and the plasmid
for His-ubiquitin was kindly provided by Dr. Park TJ
(Ajou University School of Medicine, Suwon). The
plasmids for parkin point mutants (T240R and T415N)
were constructed using the QuickChange site-directed
mutagenesis kit (Stratagene, La Jolla, CA). The plasmid
for cav-1-EGFP was constructed using PCR. All constructs
were verified by DNA sequencing and prepared using the
Endo-Free plasmid Maxi prep Kit (Qiagen, Valencia, CA)
to remove endotoxin contamination. siRNA for murine
cav-1 was purchased from Bioneer (Deajeon, Korea).
Lentiviral shRNA was constructed using the shRNA
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plasmid for rat cav-1 (GeneCopoeia, Rockville, MD ), as
described previously [80].
Western blotting and immunoprecipitation
Cells were solubilized in lysis buffer containing
50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.25 %
sodium deoxycholate, 1 % Triton X-100, and protease
inhibitor mixture (GenDEPOT, Barker, TX) for 30 min on
ice. The lysates were cleared by centrifugation at
20,000 × g for 15 min at 4 °C. The supernatants were
mixed with 5 × sample buffer, resolved by SDS-PAGE,
transferred to PVDF membrane, and analyzed by immuno-
blotting using the indicated antibodies. For immunopre-
cipitation, precleared supernatants were incubated with
antibody-bound protein G beads (Millipore, Billerica,
MA) for 6 h at 4 °C and washed four times with lysis
buffer. Immunoprecipitates were subjected to Western
blotting.
Isolation of the lipid rafts fraction
Cells were washed twice with ice-cold PBS and lysed in
ice-cold PBS containing 1 % Triton X-100 and protease
inhibitor mixture. Following incubation for 20 min at
4 °C, the lysates were centrifuged at 20,000 × g for
15 min at 4 °C. Supernatants were used as soluble frac-
tions. The pellets were washed with ice-cold PBS buffer,
solubilized with 1 X sample buffer and used as insoluble
fractions. These individual fractions were analyzed by
SDS-PAGE and Western blotting.
Quantitative real-time PCR
Total RNA was extracted from cells using Trizol reagent
(Invitrogen, Carlsbad, CA) and cDNA was prepared using
avian myeloblastosis virus RT (Promega, Fitchburg, WI)
according to the manufacturer’s instruction. cDNA sam-
ples were analyzed by the Rotor-Gene SYBR Green PCR
Master mix kit on Rotor-Gene cyclers (QIAGEN, Hilden,
Germany). The following primers were used: murine
caveolin-1 forward, 5′- CGT AGA CTC CGA GGG ACA
TC-3′ and reverse, 5′- TCC CTT CTG GTT CTG CAA
TC -3′; murine caveolin-2; forward, 5′- CTC AAG CTA
GGC TTC GAG GA-3′ and reverse, 5′- GCA AGA
CCA TTA GGC AGG TC - 3′; murine flotilin-1; for-
ward, 5′- AGA AGC CTT CCA GAT GTA CC-3′ and
reverse, 5′- ATG TCC AGT ACT TCC CCA GT - 3′;
murine flotilin-2; forward, 5′- TAA GGC TGA GGC
CTA CCA GA -3′ and reverse, 5′- AGC AGC CGG
TTT ACT TCT GA - 3′; murine actin; forward, 5′-
TGT TAC CAA CTG GGA CGA CA - 3′ and reverse,
5′-GGG GTG TTG AAG GTC TCA AA - 3′. Gene ex-
pression was normalized to the endogenous housekeeping
control gene, β-actin, which was not influenced by parkin
deficiency. Relative expression was calculated for each
gene using the Δ Δ CT (where CT is the threshold cycle)
method. Statistical analysis of reverse-transcription-PCR
(RT-PCR) data was based on duplicate samples.
In situ proximity ligations assay (PLA)
The PLA was performed using the DuoLink PLA kit
(Sigma-Aldrich, St. Louis, MO, USA) according to the
manufacturer’s instructions. Briefly, cells were fixed
with 4 % paraformaldehyde and permeabilized with
0.1 % Triton X-100. Following treatment with DuoLink
blocking buffer, cells were incubated with diluted
primary antibodies against parkin and cav-1. After
washing, cells were incubated with species-specific PLA
probes and two additional oligonucleotides under
hybridization conditions. Hybridization occurs when
PLA probes are in close proximity, which can be subse-
quently ligated to form a closed circle. A rolling-circle
amplification step follows with polymerase to generate a
concatemeric product, which can be visualized with
fluorephore-labeled oligonucleotides after hybridization.
The slides were stained with DAPI and analyzed using
confocal microscopy (Zeiss, Germany).
Measurement of membrane fluidity using C-laurdan
MEF cells and primary cortical neurons cultured on poly-
D-lysine coated glass were incubated with cell culture
media containing 0.5 μM C-laurdan (SFP Co., Ltd,
Chungbuk, Korea) for 20 min at 37 °C. The membrane
fluidity was observed using two-photon fluorescence
images, which were obtained with spectral confocal multi-
photon microscopes (Leica TCS SP2, Wetzlar, Germany).
The intensity images of C-laurdan were recorded with
emissions in the range of 400–460 nm and 470–530 nm,
with two channels of PMTs. Generalized polarization (GP)
values for each pixel were obtained using the GP analysis
program, an ImageJ plugin program and were processed
as described previously [30]. GP values ranged from -1,
corresponding to the highest fluidity, to +1 for the lowest
fluidity.
Total cellular lipid extract and quantification of
cholesterol
Total cellular lipid was extracted using the Bligh-Dyer
method [81]. Briefly, 3 ml chloroform:methanol (2:1,v/v)
was added to 1 ml medium containing 106 cells,
followed by vigorous vortexing for 15 min. One ml of
1 M NaCl was then added to the solution and vortexed
for several seconds, and the mixture was centrifuged at
low speed to separate the two phases (2,000 rpm for
15 min at room temperature). The upper phase was re-
moved by a glass pipette and discarded. The interface was
rinsed once with methanol:water (1:1) without mixing the
whole preparation. The lower chloroform phase, containing
lipids, was carefully transferred to fresh tubes and evapo-
rated under N2 gas. The lipid residue was resuspended in
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phosphate buffer containing 0.1 M potassium phosphate,
pH 7.4, 50 mM NaCl, 5 mM cholic acid, and 0.1 % Triton
X-100. Total cholesterol levels were quantified using an
Amplex Red cholesterol assay (Life Technologies, Carsbad,
CA) according to the manufacturer’s instruction.
Confocal microscopy
Cells cultured on poly-D-lysine coated coverslips were
washed twice with PBS and fixed in 4 % paraformaldehyde
for 30 min at room temperature. The fixed cells were then
washed with PBS and incubated with PBS containing
0.1 % Triton X-100 for 5 min at room temperature. After
washing several times with PBS, cells were blocked with
PBS containing 1 % bovine serum albumin (BSA) and
0.1 % Triton X-100 for 30 min at room temperature, and
then incubated overnight with primary antibodies at 4 °C.
Preparations were then stained with fluorescence-
conjugated secondary antibodies for 2 h, mounted with
vectashield (Vector Laboratories, Burlingame, CA), and
observed under a confocal microscope (Zeiss, Germany).
Statistical analysis
All values are expressed as the mean ± SEM. Statistical
significance was evaluated using the Graphpad software
(San Diego, CA).
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